Mariusz Kwiatkowski

871 total citations
11 papers, 55 citations indexed

About

Mariusz Kwiatkowski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mariusz Kwiatkowski has authored 11 papers receiving a total of 55 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mariusz Kwiatkowski's work include Cancer Immunotherapy and Biomarkers (9 papers), Prostate Cancer Treatment and Research (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Mariusz Kwiatkowski is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Prostate Cancer Treatment and Research (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Mariusz Kwiatkowski collaborates with scholars based in United States, Spain and Italy. Mariusz Kwiatkowski's co-authors include Jóse Ángel Arranz Arija, Ray Manneh Kopp, Kathryn Bylow, Fred Saad, Şuayib Yalçın, David R. Fogelman, Raffaele Ratta, Gero Kramer, Giuseppe Procopio and Neha P. Amin and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Future Oncology.

In The Last Decade

Mariusz Kwiatkowski

10 papers receiving 55 citations

Peers

Mariusz Kwiatkowski

ONCOL

PRM

IMMUN

PFM

SURGE

Suxia Luo China

J. Martin-Babau France

Emily Prince United States

Dafina Nikolova North Macedonia

S. Marimuthu United States

Diana Bello Roufai France

Arrien A. Bertram United States

Jason T. Romancik United States

Leilana Ly United States

Jaseela Chiramel United Kingdom

Suxia Luo China

Mariusz Kwiatkowski

47 ×1.2

ONCOL

38 ×1.1

PRM

13 ×0.9

IMMUN

6 ×0.5

PFM

19 ×2.1

SURGE

Citations per year, relative to Mariusz Kwiatkowski Mariusz Kwiatkowski (= 1×) peers Suxia Luo

Countries citing papers authored by Mariusz Kwiatkowski

Since Specialization

Citations

This map shows the geographic impact of Mariusz Kwiatkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mariusz Kwiatkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mariusz Kwiatkowski more than expected).

Fields of papers citing papers by Mariusz Kwiatkowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mariusz Kwiatkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mariusz Kwiatkowski. The network helps show where Mariusz Kwiatkowski may publish in the future.

Co-authorship network of co-authors of Mariusz Kwiatkowski

This figure shows the co-authorship network connecting the top 25 collaborators of Mariusz Kwiatkowski. A scholar is included among the top collaborators of Mariusz Kwiatkowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mariusz Kwiatkowski. Mariusz Kwiatkowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Gratzke, Christian, Mustafa Özgüroğlu, Mehmet Alı Nahıt Şendur, et al.. (2025). Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study. Annals of Oncology. 36(8). 964–975. 1 indexed citations

Amsberg, Gunhild von, Urban Emmenegger, Debbie Robbrecht, et al.. (2025). Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology. 43(16_suppl). 5059–5059.

Aksoy, Sercan, Marta Gil-Martín, Christoph Roderburg, et al.. (2024). 401P Vibostolimab coformulated with pembrolizumab (vibo/pembro) + chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study. Annals of Oncology. 35. S163–S164. 1 indexed citations

Rojas, Carlos A., Ferry A.L.M. Eskens, François Ghiringhelli, et al.. (2024). Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.. Journal of Clinical Oncology. 42(16_suppl). 5502–5502. 2 indexed citations

Rimassa, Lorenza, Daneng Li, Masafumi Ikeda, et al.. (2024). Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.. Journal of Clinical Oncology. 42(3_suppl). 484–484. 1 indexed citations

Graff, Julie N., Mauricio Burotto, Peter C.C. Fong, et al.. (2023). 1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study. Annals of Oncology. 34. S957–S957. 13 indexed citations

André, Thierry, Filippo Pietrantonio, Antonio Avallone, et al.. (2023). KEYSTEP-008: Phase II Trial of Pembrolizumab-Based Combination in MSI-H/dMMR Metastatic Colorectal Cancer. Future Oncology. 19(37). 2445–2452. 8 indexed citations

Gratzke, Christian, Mustafa Özgüroğlu, Mehmet Alı Nahıt Şendur, et al.. (2023). 1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study. Annals of Oncology. 34. S957–S958. 8 indexed citations

Sharma, Padmanee, Michael Krainer, Fred Saad, et al.. (2023). Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.. Journal of Clinical Oncology. 41(6_suppl). 22–22. 17 indexed citations

10.

André, Thierry, Mahmut Gümüş, Joong Bae Ahn, et al.. (2022). Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC).. Journal of Clinical Oncology. 40(16_suppl). TPS3639–TPS3639. 2 indexed citations

11.

Kwiatkowski, Mariusz, et al.. (2015). How Six Sigma brought saving and improved manufacturing process by 98.9%. 1–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact